A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40

Trial Profile

A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs BNZ 1 (Primary)
  • Indications Spinal cord disorders; T-cell leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors Bioniz
  • Most Recent Events

    • 02 Nov 2017 According to a Bioniz media release, new data will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 19 Jul 2017 According to a Bioniz Therapeutics media release, the company plans to report detailed results from this Phase 1 study at an upcoming scientific conference.
    • 19 Jul 2017 According to a Bioniz Therapeutics media release, the company announced top-line results from this BNZ-1 study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top